Comparison of Changes in Eye Findings of Premenopausal and Postmenopausal Women

CURRENT STATUS: UNDER REVIEW

BMC Ophthalmology

Ramazan Birgül
Ministry of Health Kırıkhan State Hospital

ramazanbirgul@hotmail.com

ORCiD: https://orcid.org/0000-0001-5097-3087

Gökçe Turan
Gazi Universitesi

DOI: 10.21203/rs.3.rs-19153/v1

SUBJECT AREAS
Ophthalmology

KEYWORDS
Menopause, Corneal thickness, Refractive value, Ocular axial length, Blepharitis
Abstract

**Background:** This study aimed to compare the presence of blepharitis with corneal thickness, refractive values and ocular axial length changes in premenopausal and postmenopausal women.

**Methods:** Thyroid-stimulating hormone (TSH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), oestradiol (E2), refractive values with prolactin, refractions in horizontal and vertical meridians, ocular tension (OT) values, ocular axial length, central corneal thickness and the presence of blepharitis were evaluated in 142 premenopausal patients and 153 postmenopausal patients.

**Results:** Statistically significant differences were found for the values for right eye OT (P < 0.001), left eye OT (P < 0.001) and presence of blepharitis in the premenopausal group (p<0.001). There appears to be no relationship between the decrease in corneal refractive values and increased corneal thickness or ocular axial length. However, the presence of blepharitis and increased OT values are related.

**Conclusions:** Woman in postmenopausal period should be examined by ophthalmologist because of significant increase in blepharitis and OT.

**Background**

Menopause is defined as the absence of menstruation in women for 1 or more years. (1) Structural and functional changes occur during the postmenopausal period, including ocular changes. (2) These changes are caused by alterations in hormones, especially oestrogen (E2) deficiency. (2,3) The presence of E2, progesterone and androgen receptors in the lacrimal gland, the meibomian gland, conjunctiva and corneal epithelium form the basis of these changes. (4) The effects of E2 on the cornea, where light is diffracted in the eye, vary. The eye features most affected by these changes are the central corneal thickness and refraction in the horizontal and vertical meridians of the cornea. (2,4,5) Studies have also found that E2 affects ocular tension (OT). (6,7) The changes in these ocular components can decrease functional effectiveness in terms of visual physiology. (5) Most of the recent studies related to the effects of the postmenopausal period on eye health have focused on eye dryness. (4,5,8) Because of hormonal imbalances during this period, tear production and stability are deteriorated and ocular tissues become vulnerable to microorganisms. (9) This is
mainly due to the changes in the meibomian gland, the lipid layer that forms the outermost tear layer, which becomes thinner, reducing the quality of tears. (10) Generally, this decrease in the lipid layer occurs due to infection and inflammation of meibomian glands, known as posterior blepharitis. (11,12) Blepharitis is a general condition characterized by infection and inflammation of eyelids, including the roots of eyelashes. Bacteria such as *Staphylococcus epidermidis* and *Propionibacterium acnes* are among the most common agents. (13)

This study aimed to compare the refraction, corneal refraction in horizontal and vertical meridians, central corneal thickness, ocular tension (OT), ocular axial length changes and presence of blepharitis in premenopausal and postmenopausal women.

**Methods**

This prospective case-control study was conducted between January 2018 and July 2019 in a second-line hospital. Premenopausal and postmenopausal patients admitted to the gynaecology outpatient clinic for routine gynaecological control between the ages of 40–45 were included in the study after receiving informed consent from all participants and approval from the ethics committee (ethics committee approval no: 2019/38). Postmenopausal women were defined as those who had not menstruated for 1 year or more. Patients with oophorectomy-induced artificial menopause, a history of premature menopause, systemic disease, history of ocular trauma or surgery, inflammatory eye disease, diabetes mellitus (DM), glaucoma, corneal pathology or conjunctival pathology were excluded from this study. Additionally, patients receiving hormone replacement therapy (HRT), who were pregnant or who wore contacts were also excluded. Patients included in the study were divided into two groups: postmenopausal (study group) and premenopausal (control group). The ages and gravida parity values of the patients were recorded, and gynaecological examinations were performed. Thyroid-stimulating hormone (TSH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), E2 and prolactin levels of all participants were recorded.

After the gynaecological examination, all participants were given an eye examination. Refraction values and keratometric values in the horizontal and vertical meridian (dioptre[D]) of both eyes were measured with anARK-700 auto-refractometer. Ocular tension values (mmHg) were measured with
Reichert 7 air tonometry. Ocular axial length (mm) and central corneal thickness (µm) were measured with Topcon noncontact microscopy. The presence of blepharitis was determined with biomicroscopy by observing inflammation of the eyelid skin and eyelash follicles, erythema, squamous debris, shedding of eyelashes, foamy tears and obstruction of the meibomian gland.

The demographic findings, laboratory values and ophthalmologic findings of both groups were recorded and compared with each other. E2 values and eye examination findings were evaluated by correlation analysis.

In this study, statistical analyses were performed using SPSS 20.0 (IBM, Armonk, NY, USA). Descriptive statistics for continuous (quantitative) variables are expressed as means and standard deviations, while categorical variables are expressed as numbers (n) and percentages (%). The suitability of the variables to normal distribution was evaluated by visual and analysis methods, and parametric tests were used due to their suitability for normal distribution. Chi-square and Fisher’s exact tests were used to calculate the demographic characteristics of the patients. Pearson’s rank correlation test was used for univariate correlation analysis. The two groups of dependent and independent data were analyzed with Student’s t-test. The ANOVA test was used when three or more variables were available. A p-value less than 0.05 was considered significant.

Results

Between January 2018 and July 2019, a total of 322 patients were admitted to the gynaecology outpatient clinic of a second-line hospital. Of these, 15 patients had a history of glaucoma, 5 patients had previous ocular surgery, 4 patients had a history of premature menopause, and 3 patients had a hysterectomy and bilateral oophorectomy. These 27 patients were excluded from the study, and the remaining 295 patients were included in the study. The patients were divided into two groups: 142 premenopausal patients and 153 postmenopausal patients. Demographic data, hormone values and ophthalmologic findings of the patients are listed in Table 1. There were no significant differences between the participants’ age, gravida and parity values. While FSH levels of postmenopausal patients were significantly higher than those of premenopausal patients (p = 0.02), no differences were found between the two groups regarding TSH, LH, E2 and prolactin values. Significant
differences were found between the groups regarding right eye refraction (p = 0.02), left eye refraction (p = 0.02), right eye OT (p < 0.001) and left eye OT (p < 0.001) values. There were no significant differences between the values for right eye horizontal keratometry, left eye horizontal keratometry, right eye vertical keratometry, left eye vertical keratometry, right eye axial, left eye axial, right eye central corneal thickness and left eye central corneal thickness. The presence of blepharitis in the postmenopausal group was significantly higher than in the premenopausal group (p < 0.001). When the correlation analysis between the E2 value and eye measurements was examined, no significant difference was observed (Table 2).

| Measurement | Postmenopausal patients (n = 142) (Mean ± SD) | Premenopausal patients (n = 153) (Mean ± SD) | P-value |
|-------------|---------------------------------------------|---------------------------------------------|---------|
| Age (Years) | 42.95 ± 2.15 | 43.00 ± 2.09 | 0.620 |
| Gravida     | 3.35 ± 1.67  | 3.24 ± 1.81  | 0.950 |
| Parity      | 1.28 ± 1.09  | 1.35 ± 1.42  | 0.690 |
| FSH         | 24.10 ± 11.67| 11.75 ± 8.60 | 0.020 |
| LH          | 16.67 ± 11.82| 17.72 ± 6.76 | 0.820 |
| E2          | 95.91 ± 104.53| 117.77 ± 90.35 | 0.270 |
| TSH         | 1.93 ± 1.02  | 1.77 ± 1.12  | 0.540 |
| Prolactin   | 12.94 ± 7.32 | 12.63 ± 7.59 | 0.870 |
| Refraction value | | | |
| Right eye   | 0.17 ± 1.39  | -0.47 ± 1.11 | 0.020 |
| Left eye    | 0.20 ± 1.48  | -0.42 ± 0.94 | 0.020 |
| OT          | 17.11 ± 1.73 | 15.71 ± 2.72 | <0.001 |
| Horizontal keratometry | | | |
| Right eye   | 43.16 ± 1.50 | 43.21 ± 1.44 | 0.880 |
| Left eye    | 43.28 ± 1.75 | 43.31 ± 1.51 | 0.930 |
| Vertical keratometry | | | |
| Right eye   | 43.42 ± 1.49 | 43.95 ± 1.65 | 0.150 |
| Left eye    | 43.53 ± 1.60 | 43.87 ± 1.53 | 0.310 |
| Axial measurement value | | | |
| Right eye   | 23.02 ± 0.79 | 22.90 ± 0.90 | 0.550 |
| Left eye    | 22.96 ± 0.87 | 22.81 ± 0.87 | 0.440 |
| Pachymetry value | | | |
| Right eye   | 545.45 ± 28.74 | 537.50 ± 34.28 | 0.360 |
| Left eye    | 547.82 ± 28.04 | 537.68 ± 34.84 | 0.200 |
| Blepharitis | | | |
| Present     | 99 (69.70%) | 81 (52.90%) | <0.001 |
| None        | 43 (30.29%) | 72 (47.00%) | |

Table 1
Demographic data, laboratory findings and eye examination findings
Table 2
Correlation analysis of the relationship between E2 value and eye measurements

| Measurement                        | P-value |
|-----------------------------------|---------|
| Refraction value                  |         |
| Right eye                         | 0.66    |
| Left eye                          | 0.68    |
| OT                                |         |
| Right eye                         | 0.30    |
| Left eye                          | 0.78    |
| Horizontal keratometry            |         |
| Right eye                         | 0.26    |
| Left eye                          | 0.32    |
| Vertical keratometry              |         |
| Right eye                         | 0.13    |
| Left eye                          | 0.12    |
| Axial value                       |         |
| Right eye                         | 0.16    |
| Left eye                          | 0.41    |
| Central corneal thickness         |         |
| Right eye                         | 0.67    |
| Left eye                          | 9.52    |

Discussion

The perimenopausal period is characterized by the loss of sex hormones and is accompanied by a series of changes in the body. Regarding the visual system, changes can occur to the corneal and ocular surfaces. (14) This study mainly examined the effects of E2 on these two tissues in the postmenopausal period.

The effect of postmenopausal E2 depletion on the lacrimal gland, the meibomian gland, conjunctiva and cornea is different in each tissue. The effect of E2 on the meibomian gland is proinflammatory; its effect on the lacrimal gland and the corneal epithelium is unclear but is believed to be either pro-inflammatory or anti-inflammatory. (15) Studies have reported that E2 changes corneal thickness and that corneal thickness significantly decreases as E2 decreases. (4,16) However, another recent study reported that the relationship between E2 deficiency and reduced corneal thickness was non-significant. (17) In our study, although E2 was decreased in postmenopausal patients, corneal thickness was increased, but the results were not significant. During the postmenopausal period, other hormones besides E2 also decrease in normal physiology. For example, studies have reported that decreased thyroxine hormone, which has receptors in the cornea, is correlated with increased corneal thickness during menopause. (18,19) This suggests that changes in corneal thickness in postmenopausal people is not only related to E2 but other hormones as well.

In a study examining the relationship between E2 and corneal refraction, there was no significant
correlation between changes in E2 and corneal refraction in the postmenopausal period; however, a significant correlation was found between horizontal corneal refraction and E2. (2) In addition, horizontal refraction was slightly increased in that study.² In other studies, no significant changes were found in horizontal and vertical corneal refractions in the postmenopausal period. (4,20) In our study, although both vertical and horizontal refraction levels were decreased, this decrease was not significant. The correlation analysis revealed a relationship between vertical refraction and E2, but it was not significant.

Changes in the refraction of the eye primarily result from changes in the cornea, lens and axial length. (21) In our study, we showed that the relationship between decreased corneal refraction and increased corneal thickness and ocular axial length in the postmenopausal period was not significant. The fact that refraction is negative (-) in the premenopausal period and positive (+) in the postmenopausal period was attributed to hypermetropic changes due to the cataract course in the lens as a result of aging rather than hormonal changes.

One study showed that the decrease in E2 in postmenopausal women increases the ocular tension in different ways. (7) It is thought that E2 reduction has an antagonistic effect on the carbonic anhydrase pump in the corneal endothelium, decreasing the uveoscleral flow and increasing the episcleral venous pressure. (7,16) Thus, ocular tension is increased. In accordance with the literature, we also found significantly increased ocular tension in postmenopausal women.

E2 has a proinflammatory effect on meibomian glands, which results in reduced lipid production from the meibomian glands located on the eyelids. (15) This creates two major consequences. First, the lipid layer (the outermost layer of the tear layer) decreases, resulting in eye dryness. (22) Accordingly, most of the recent studies in the literature have focused on the incidence of eye dryness in the postmenopausal period. (5,9,23) Second, the meibomian gland orifices are occluded, which increases the eyelids' exposure to microorganisms due to the impaired circulation there. Thus, a condition of blepharitis, characterized by inflammation and infection in the eyelids, may develop. (9,12) No studies have directly investigated the incidence of blepharitis in the postmenopausal period, making this study novel. In our study, the blepharitis rate was significantly increased in the
postmenopausal period. In normal physiology, the incidence of blepharitis is expected to decrease in the postmenopausal period, which is characterized by a decrease in E2. This paradoxical situation suggests that other hormones have an effect on meibomian glands as well. It is known that androgens have an anti-inflammatory effect on meibomian glands, reducing the incidence of blepharitis. (24) In the postmenopausal period, there is a decrease in androgens along with a decrease in E2. (9) Thus, the increased incidence of blepharitis in the postmenopausal period is likely due to this decrease in androgens.

Conclusion
Many hormones, especially E2, cause ocular changes in postmenopausal women. There appears to be no relationship between the decrease in corneal refractive values and increased corneal thickness or ocular axial length. However, the presence of blepharitis and increased OT values are related. Thus woman in postmenopausal period should be examined by ophthalmologist because of significant increase in blepharitis and OT.

Declarations

**Ethics approval and consent to participate**

This study complied with the tenets of the Declaration of Helsinki and was approved by the Medical Ethics Committee of Mustafa Kemal University. Informed consent was given by every subject prior to enrolment. Ethics committee approval no: 2019/38

**Consent for Publication**

Not applicable

**Availability of data and materials**

The first author has full access to all the data.

**Abbreviations**

TSH: Thyroid-stimulating hormone; FSH: Follicle-stimulating hormone; LH: Luteinizing hormone; E2: Oestradiol (E2); OT: Ocular tension; DM: Diabetes mellitus; HRT: Hormone replacement therapy; D: Dioptre; ANOVA: Analysis of variance

**Competing interests**
The authors declare that they have no competing interests

Acknowledgements

Not applicable

Funding

All authors declare that they received no funding for this study

References

1. del Ghianda S, Tonacchera M, Vitti M. P. Thyroid and menopause. Climacteric. 2014 Jun;17(3):225–34.

2. Aydin E, Demir HD, Demirturk F, Caliskan AC, Aytan H, Erkorkmaz U. Corneal topographic changes in premenopausal and postmenopausal women. BMC Ophthalmol. 2007 May 14;7;9.

3. Castellanos-Gonzalez JA, Torres-Martinez V, Martinez-Ruiz A, et al. Prevalence of dry eye sendrome in residents of surgical specialties. BMC Ophthalmol. 2016 Jul;16:16:108.

4. Turgut FG, Turgut A, Dolgun ZN, Köröglu N. Effects of menopause on corneal topography and dry eye. Int J Reprod Contracept Obstet Gynecol. 2017 Feb;6(2):461–5.

5. Versura P, Giannaccare G, Campos EC. Sex-Steroid imbalance in females and dry eye. Cur Eye Res. 2015 Feb;40(2):162–75.

6. Ojha P, Wiggs JL, Pasquale LR. The genetics of intraocular pressure. Semin Ophthalmol. 2013 Sep-Nov;28(5–6):301–5.

7. Candar A, Dane C, Yumuşak E, Kalemli M. Postmenopozal kadınlarda göziçi basıncının değerlendirilmesi. T Klin Oftalmoloji. 2000, 9;98-101.

8. Yeo S, Tong L. Coping with dry eyes: a qualitative approach. BMC Ophtalmol. 2018 Jan 16;18(1):8.

9. Truong S, Cole N, Stapleton F, Golebiowski B. Sex hormones and the dry eye. Clin Exp
10. Chhadva P, Goldhardt R, Galor A. Meibomian gland disease: the role of gland dysfunction in dry eye disease. Ophthalmology. 2017 Nov;124(11S):20–6.

11. AlDarrab A, Alrajeh M, Alsuhaibani AH. Meibography for eyes with posterior blepharitis. Saudi J Ophthalmol. 2017 Jul-Sep;31(3):131-4.

12. Bernardes TF, Bonfioli AA. Blepharitis. Semin Ophthalmol. 2010 May;25(3):79-83.

13. Eroglu S, Cakmakliogullari M, Kal Cakmakliogullari E. Is the presence of Demodex folliculorum increased with impaired glucose regulation in polycystic ovary syndrome? J Obstet Gynaecol. 2019 Sep;10:1-5.

14. Gipson IK. Age-related changes and diseases of the ocular surface and cornea. Invest Ophthalmol Vis Sci. 2013 Dec;13(14):ORSF48-53.54.

15. Golebiowski B, Badarudin N, Eden J, Gerrand L, Robinson J, Liu J, Hampel U, You J, Stapleton F. The effects of transdermal testosterone and oestrogen therapy on dry eye in postmenopausal women: a randomised, placebo-controlled, pilot study. Br J Ophtalmol. 2017 Jul;101(7):926–32.

16. Kalogeropoulos D, Sung VC, Paschopoulos M, Moschos MM, Panidis P, Kalogeropoulos C. The physiologic and pathologic effects of pregnancy on the human visual system. J Obstet Gynaecol. 2019 Nov;39(8):1037–48.

17. Bahadir Kilavuzoglu AE, Cosar CB, Bildirici I, Cetin O, Ozbasli E. Estrogen and progesterone induced variation in corneal parameters according to hormonal status. Eye Contact Lens. 2018 Sep;44(Supply 1):179–84.

18. Gatzioufas Z, Panos GD, Brugnolli E, Hafezi F. Corneal topographical and biomechanical variations associated with hypothyroidism. J Refract Surg. 2014 Feb;30(2):78-9.

19. Thanos S, Oellers P, Meyer Zu Hörste M, Prokosch V, Schlatt S, Seitz B, Gatzioufas Z.
Role of thyroxine in the development of keratoconus. Cornea. 2016 Oct;35(10):1338-46.

20. Cavdar E, Ozkaya A, Alkin Z, Ozkaya HM, Babayigit MA. Changes in tear film, corneal topography, and refractive status in premenopausal women during menstrual cycle. Contact Lens Anterior Eye. 2014 Jun;37(3):209-12.

21. Yanoff M, Duker JS. Optics and refraction. *Ophthalmology*. Mosby, London; 1998(2):8.2.

22. Schaumberg DA, Nichols JJ, Papas EB, Tong L, Uchino M, Nichols KK. The international workshop on meibomian gland dysfunction: report of the subcommittee on the epidemiology of, and associated risk factors for, MGD. *Invest Ophthalmol Vis Sci*. 2011 Mar 30;52(4):1994–2005.

23. Peck T, Olsakovsky L, Aggarwal S. Dry eye syndrome in menopause and perimenopausal age group. J Midlife Health. 2017 Apr-Jun;8(2):51–4.

24. Sullivan DA, Sullivan BD, Evans JE, Schirra F, Yamagami H, Liu M, Richards SM, et al. Androgen deficiency, meibomian gland dysfunction, and evaporative dry eye. Ann N Y Acad Sci. 2002 Jun;966:211-22.